SLC13A5 and metabolic dysfunction-associated steatohepatitis: Moreover, additional studies are required to determine whether NaCT inhibition acts synergistically with other drugs that are currently in clinical development for NASH, such as GLP1, thyroid hormone receptor (THR) β, farnesoid X receptor (FXR), or PPAR agonists.